Saurashtra News

Dry Eye Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Dry Eye Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

February 21
07:32 2023
Dry Eye Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Dry Eye Disease pipeline constitutes key companies continuously working towards developing Dry Eye Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Dry Eye Disease Overview

Dry eye disease (DED), also known as dry eye syndrome (DES), keratoconjunctivitis sicca (KCS), and keratitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular suface inflammation and damage, and neurosensory abnormalities.

 

Dry Eye Disease Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Eye Disease Market.

 

The Dry Eye Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Dry Eye Disease Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dry Eye Disease treatment therapies with a considerable amount of success over the years. Dry Eye Disease Key players such as – Quorum Innovations, Serentrix, Cellix Bio, Taejoon Pharmaceutical Co., Ltd., Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc., Aramis Biosciences, Kowa Research Institute, Inc., Aerie Pharmaceuticals, HanAll Biopharma, Seikagaku Corporation, Novaliq GmbH, and others, are developing therapies for the Dry Eye Disease treatment 
  • Dry Eye Disease Emerging therapies such as – Qi 401, SER-114, CLX-OPH-621, TJO-083, SY-201, INV-102, GLH8NDE,SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others are expected to have a significant impact on the Dry Eye Disease market in the coming years.   

 

Route of Administration

Dry Eye Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Dry Eye Disease Pipeline Therapeutics Assessment

  • Dry Eye Disease Assessment by Product Type
  • Dry Eye Disease By Stage and Product Type
  • Dry Eye Disease Assessment by Route of Administration
  • Dry Eye Disease By Stage and Route of Administration
  • Dry Eye Disease Assessment by Molecule Type
  • Dry Eye Disease by Stage and Molecule Type

 

DelveInsight’s Dry Eye Disease Report covers around products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Dry Eye Disease Therapeutics Market include:

Key companies developing therapies for Dry Eye Disease treatment are – AbbVie Inc. (Allergan PLC), AFT Pharmaceuticals, Akorn, Alcon Inc., Bausch Health Companies Inc., Horus Pharma, Johnson & Johnson, Mitotech, Novaliq GmbH, OASIS Medical, Otsuka Pharmaceutical Co. Ltd, Prestige Consumer Healthcare, Santen Pharmaceutical Co. Ltd, Sentiss Pharma Pvt. Ltd, Sun Pharmaceutical Industries Ltd, and VISUfarma, and others.

 

Emerging Dry Eye Disease Drugs Under Different Phases of Clinical Development Include:

  • Qi 401: Quorum Innovations
  • SER-114: Serentrix
  • CLX-OPH-621: Cellix Bio
  • TJO-083: Taejoon Pharmaceutical Co., Ltd.
  • SY-201: Seinda Pharmaceutical
  • INV-102: Invirsa
  • GLH8NDE: GL Pharm Tech Corporation
  • SHJ 002: Dreamhawk Vision Biotech, Inc.
  • A197: Aramis Biosciences
  • K-161: Kowa Research Institute, Inc.
  • AR-15512: Aerie Pharmaceuticals
  • HL036: HanAll Biopharma        
  • SI-614: Seikagaku Corporation
  • NOV03: NovaliqGmbH
  • CyclASol: NovaliqGmbH

 

Get a Free Sample PDF Report to know more about Dry Eye Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/dry-eye-disease-pipeline-insight

 

Dry Eye Disease Pipeline Analysis:

The Dry Eye Disease pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dry Eye Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Eye Disease Treatment.
  • Dry Eye Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dry Eye Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Eye Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Dry Eye Disease product details are provided in the report. Download the Dry Eye Disease pipeline report to learn more about the emerging Dry Eye Disease therapies

 

Dry Eye Disease Pipeline Market Drivers

  • Rise in geriatric population
  • Increasing Exposure to computer screens
  • Increased R&D Activities
  • Adoption of new Technologies

 

Dry Eye Disease Pipeline Market Barriers

  • Lack of awareness about dry eye disease in low income countries
  • Complexity of the disease
  • Challenges associated with the Ocular drug delivery

 

Scope of Dry Eye Disease Pipeline Drug Insight    

  • Coverage: Global
  • Key Dry Eye Disease Companies: Quorum Innovations, Serentrix, Cellix Bio, Taejoon Pharmaceutical Co., Ltd., Seinda Pharmaceutical, Invirsa, GL Pharm Tech Corporation, Dreamhawk Vision Biotech, Inc., Aramis Biosciences, Kowa Research Institute, Inc., Aerie Pharmaceuticals, HanAll Biopharma, Seikagaku Corporation, NovaliqGmbH, and others
  • Key Dry Eye Disease Therapies: Qi 401, SER-114, CLX-OPH-621, TJO-083, SY-201, INV-102, GLH8NDE,SHJ 002, A197, K-161, AR-15512, HL036, SI-614, NOV03, CyclASol, and others
  • Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
  • Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers 

 

Request for Sample PDF Report for Dry Eye Disease Pipeline Assessment and clinical trials

 

Table of Contents

1

Dry Eye Disease Report Introduction

2

Dry Eye Disease Executive Summary

3

Dry Eye Disease Overview

4

Dry Eye Disease- Analytical Perspective In-depth Commercial Assessment

5

Dry Eye Disease Pipeline Therapeutics

6

Dry Eye Disease Late Stage Products (Phase II/III)

7

Dry Eye Disease Mid Stage Products (Phase II)

8

Dry Eye Disease Early Stage Products (Phase I)

9

Dry Eye Disease Preclinical Stage Products

10

Dry Eye Disease Therapeutics Assessment

11

Dry Eye Disease Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dry Eye Disease Key Companies

14

Dry Eye Disease Key Products

15

Dry Eye Disease Unmet Needs

16 

Dry Eye Disease Market Drivers and Barriers

17

Dry Eye Disease Future Perspectives and Conclusion

18

Dry Eye Disease Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Dry Eye Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/r-and-d-analysis